Taysha Gene Therapies, Inc. (TSHA) Form 424B5 — Jun 25, 2026
Taysha Gene Therapies announced the pricing of a public offering of 32,500,001 shares of common stock and pre-funded warrants to purchase up to 833,333 shares of common stock at a public offering price of $6.00 per share and $5.999 per pre-funded warrant, respectively. The company expects to raise approximately $187.4 million in net proceeds, or approximately $215.6 million if the underwriters exercise their full option to purchase an additional 5,000,000 shares of common stock. The joint book-running managers for the offering are Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor, with Baird serving as the lead manager.
Key figures
- Cash Position
- 276
- Gross Proceeds
- 199,999,171
- Offering Price
- 6
- Shares Offered
- 32500001
- Greenshoe shares
- 5000000
- Proceeds to company
- 187,999,171
- Prefunded warrant price
- 5.999
- Prefunded warrants offered
- 833333
- Proceeds to company with greenshoe
- 216,199,171
Price after filing
Close on the filing date to close N calendar days later (from $6.21). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.